タナカ ジユンジ
TANAKA Junji
田中 淳司 所属 その他 その他 職種 非常勤嘱託 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. |
掲載誌名 | 正式名:Bone marrow transplantation 略 称:Bone Marrow Transplant ISSNコード:(1476-5365)0268-3369(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 54(8),pp.1266-1274 |
著者・共著者 | Yoshimitsu Makoto†, Utsunomiya Atae, Fuji Shigeo, Fujiwara Hiroshi, Fukuda Takahiro, Ogawa Hiroyasu, Takatsuka Yoshifusa, Ishitsuka Kenji, Yokota Akira, Okumura Hirokazu, Ishii Kazuyoshi, Nishikawa Akinori, Eto Tetsuya, Yonezawa Akihito, Miyashita Kaname, Tsukada Junichi, Tanaka Junji, Atsuta Yoshiko, Kato Koji, |
発行年月 | 2019/08 |
概要 | Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia-lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220-3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL. |
DOI | 10.1038/s41409-018-0400-5 |
PMID | 30546068 |